Liver dysfunction is associated with a variety of liver diseases, including viral or alcoholic 30 hepatitis, fibrosis, cirrhosis, and portal hypertension. A targeted drug delivery system would be very useful in the treatment of these diseases. We herein describe the development of a system comprised 
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Introduction 65
The liver is the largest organ of the body and is probably the most important power and sewage treatment plant in the body. Two major types of cells populate the liver, namely, parenchymal and non-parenchymal cells. Approximately 80% of the liver volume is made up of parenchymal cells commonly referred to as hepatocytes (Ramadori et al., 2008) . Sinusoidal endothelial cells, Kupffer cells and hepatic stellate cells are examples of non-parenchymal cells. Different types of liver 70 diseases are associated with different types of liver cells. For example viral hepatitis and alcoholic hepatitis are associated with hepatocytes. Liver endothelial cell (LEC) dysfunction is associated with variety of liver diseases, including fibrosis, cirrhosis, and portal hypertension (Dominique et al., 2010) . The defenestration of liver endothelial cells causes hyperlipidemia, because it becomes difficult for lipoproteins to reach hepatocytes (Rajkumar et al., 2010) . Kupffer cells are associated 75
with the progression of non-alcoholic steatosis and fibrosis. It has also been reported that hepatocellular stress caused by various diseases causes the release of different types of cytokines and chemokines by different types of cells which ultimately cause the transmigration of inflammatory cells towards their target, hepatocytes (Ramadori et al., 2008) . Therefore, a selective drug delivery system would be an ideal approach for achieving a subsequent efficient therapy for treating different 80 types of liver diseases.
A group of certain basic proteins or peptides have the ability to inhibit the binding of low density lipoprotein (LDL) to its receptor protein (Brown et al., 1978) . This inhibition is caused by polycations interacting with the receptor. LDLs are associated with a negatively charged LDL 85 receptor even though the net charge of this lipoprotein is also negative. This suggests that the net charge of the LDL is governed by the positive charge of the ApoB sequence. Two basic regions of similar size in ApoB-100 segments, namely 3147 through 3157 and 3359 through 3367 are part of the LDL receptor binding domain. This ApoB heterodimer binds to the LDL receptor and also binds with Glycoseaminoglycans (GAGs) with an affinity similar to that between LDL and GAGs (Urban 90 et al., 1997). The ApoB-100 segment RLTRKRGLK (3359-3367) is a mediator of the association between LDL and arterial Chondroitin sulfate-rich proteoglycan (CSPG) (Urban et al., 1993) . It has recently been reported that LEC express low density lipoprotein receptor protein-1 (LRP-1) which is a member of the LDL receptor gene family (Oie et al., 2011 ,Thomas et al., 1999 . Another study has shown that LDL is taken up by both parenchymal and non-parenchymal cells (Marit et al., 1998) . 95
Liposomes are suitable nano-carriers that have the capacity to deliver drug particles to various target cells in vitro or diseased tissues in vivo (Puri et al., 2009 , Du et al., 2007 ). Based on these considerations, we selected the ApoB segment RLTRKRGLK (3359-3367) abbreviated here as RLTR for use as a novel ligand in designing a selective targeting system for hepatocytes. 100 mg/ml solution of dihydroxybenzoic acid.
Preparation of liposomes
Liposomes (LPs) composed of EPC/Chol (molar ratio: 7/3) was prepared by the lipid hydration 140 method. A control cationic LP was prepared using DC6-14, DOPE, and Cholesterol at a molar ratio of 4:3:3 (Ishiwata et al., 2000) . RLTR peptide modified PEG-LPs (RLTR-PEG-LPs) were prepared by adding the required amount of RLTR-PEG to the lipid solution. 1 mol% Rhodamine-DOPE was incorporated, to serve as a label for the lipid component. A lipid film was produced by evaporation of the solvents (chloroform and ethanol) from a lipid solution in a glass tube. HEPES buffer (10 mM, 145 pH 7.4) was added and the solution was incubated for 10 min to hydrate the lipid film. The glass tube was then sonicated for approximately 30 sec in a bath-type sonicator (AU-25C, Aiwa, Tokyo, Japan). The mean size and zeta potential of the prepared LPs were determined using a Zetasizer Nano ZS ZEN3600 instrument (Malvern Instruments Ltd., Worchestershire, UK).
150
Isolation of Primary liver endothelial cells (Liver ECs)
Liver endothelial cells (Liver ECs) were isolated as previously described (Hida et al., 2004 , Akino et al., 2009 . Briefly, the liver of a female KSN mouse was excised. The excised tissue was minced and digested with collagenase II (Worthington, Freehold, NJ). Blood cells were removed by a single sucrose step-gradient centrifugation with Histopaque 1077 (Sigma-Aldrich), and the 155 resulting cell suspension was filtered. Endothelial cells were isolated using MACS according to the manufacturer's instructions using a FITC-anti-CD31 antibody. CD31-positive cells were sorted and plated on 1.5% gelatin-coated culture plates and grown in EGM-2MV (Clonetics, Walkersville, MD) and 10% fetal bovine serum. After subculturing for 2 weeks, the isolated ECs were purified by a second round of purification using FITC-BS1-B4 (Vector Laboratories, Burlingame, CA). All of the 160 endothelial cells were split at a ratio of 1:3.
In vitro Cellular uptake study
For the cellular uptake study, 40,000 cells were seeded in a 24-well plate (Corning incorporated, Corning, NY, USA) (40,000 cells/well). After 24 hrs, the prepared rhodamine labeled PEG-LPs/ 165 RLTR-PEG-LPs were added and incubated for an additional 3 hrs. After the incubation, the cells were washed with PBS (pH 7.4) and then treated with Reporter Lysis Buffer (Promega Corp., Madison, WI, USA) followed by centrifugation at 12,000 rpm for 5 min at 4 °C to remove debris.
The supernatants were then collected. The cellular uptake efficiency of the prepared rhodamine labeled LPs were determined by measuring the fluorescence intensity of rhodamine (excitation at 170 550 nm and emission at 590nm) using FP-750 Spectrofluorometer (JAS Co, Tokyo, Japan).
In vivo Biodistribution study
3 H-Cholesteryl hexadecyl ether (CHE) labeled LPs and RLTR-PEG-LPs were used to measure the biodistribution of liposomes in different organs in the mice. ICR mice were intravenously injected with 3 H-labeled LPs or RLTR-PEG-LPs. After 25 min, the animals were sacrificed; the portal vein 175 was cut and a needle was introduced into the vena cava and 10-15 ml of heparin containing PBS (40 units/ml) solution was used to remove the remaining blood and cell surface bound RLTR-PEG-LPs in the liver. Other organs, including the lungs and kidney were also collected and all of the collected organs were weighed. After weighing, the samples were solubilized in Soluene-350 (Perkin-Elmer Life Sciences, Japan) for overnight at 55 0 C. Samples were decolorized by treatment with H 2 O 2 . The 180 radioactivity of the samples was measured by using a liquid scintillation counting (LSC-6100, Aloka, Japan) after adding 10 ml of Hionic Flour (Perkin-Elmer Life Sciences, Japan) (Hatakeyama et al., 2004) . Tissue accumulation of LPs was represented as the percentage of injected dose (%ID) per organ.
185
Confocal microscopy experiment
ICR mice were given intravenous injection of Rhodamine labeled RLTR-PEG-LPs and the mice were killed 25 min after the treatment. The liver was perfused as mentioned in the section 2.7 and then it was collected. The liver was then excised and washed with saline and sliced into 10-15 mmsized blocks with scissors. The liver sections were then incubated with a 20 fold volume of a diluted 190 solution of Hoechst 33342 (1mg/ml) and Isolectin B4 in HEPES buffer for 1 hr. The specimens were placed on a 35 mm glass base dish (IWAKI, Osaka, Japan) and observed by confocal laser scanning microscopy (A1 Confocal Laser Microscope System, Nikon Instruments Inc., Tokyo, Japan).
Inhibition assay 195
In vivo competitive inhibition study of RLTR-PEG-LPs
ICR mice were injected with unlabeled LPs and after 15 min, they were injected with cationic LP or RLTR modified PEG-LP or KLGR (reverse peptide sequence of RLTR) modified PEG-LP. After another 25 min of incubation the mice were sacrificed and the livers were perfused with 10 ml of a 40% heparin-PBS solution. The mice livers were then collected, sliced into 0.5mm x 0.5 mm pieces, 200 stained with Hoechst 33342 and isolectin B4 and then observed by confocal microscopy (A1 Confocal Laser Microscope System, Nikon Instruments Inc., Tokyo, Japan).
In vitro competitive inhibition study of RLTR-PEG-LPs
For in vitro inhibition study unlabeled RLTR-PEG or KLGR-PEG modified LPs were used as 205 inhibitors. We previously used an excess amount of free RLTR or KLGR peptide as an inhibitor but no significant inhibition was observed (data not shown). It was reported that the monomeric free peptide might not be sufficiently effective to inhibit the interactions of multiplex RLTR-PEG-LP or KLGR-PEG-LP with the target receptor (Kibria et al., 2011) . As a result we used unlabeled RLTR-PEG or KLGR-PEG modified LP as inhibitors in order to achieve multivalent attachment with the 210 targeted receptors. Here 40,000 LECs were seeded in a 24-well plate and the plate was incubated overnight. After 24 hours, different concentrations of rhodamine labeled and unlabeled PEG-LPs
(1:0, 1:5, 1:10, 1:20 and 1:50 respectively) were added and incubated for 3 hrs. After 3 hrs, the cells were washed 3 times with 1 ml of ice-cold phosphate buffer saline (PBS) which was supplemented with heparin (20 units/ml) to completely remove the surface-bound RLTR-PEG-LP and the 215 intracellular fluorescence intensity of rhodamine was then determined (Kibria et al., 2011) .
Statistical analysis
Comparisons between multiple treatments were made using one-way analysis of variance (ANOVA), 220 followed by the 'Dunnett test'. Pair-wise comparisons of subgroups were made using the student's ttest. Differences among the means were considered to be statistically significant at a p-value of <0.05 and <0.01.
Results 225
Synthesis of RLTR-PEG-DSPE
The thiol group of the cystein residue in the RLTR peptide was conjugated by reaction with Mal-PEG 2000 -DSPE at 37°C for 24 hours (Reaction scheme is shown in the supplementary figure 1).
MALDI-TOF MS analyses confirmed the synthesis of RLTR-PEG-DSPE. 
The characteristic of RLTR-PEG-LPs and its cellular uptake
The selected RLTR peptide was attached to the top of PEG in PEGylated liposomes. PEG liposomes (PEG-LPs) and RLTR modified PEG liposomes (RLTR-PEG-LPs) were prepared by incorporating PEG-DSPE or RLTR-PEG-DSPE at levels of 1, 3, 5, or 10 mol% of the total lipid. The physical properties of the prepared LPs are shown in Table 1 . To evaluate the effect of the RLTR peptide on 235 cellular uptake, we next examined the cellular uptake of RLTR-PEG-LPs and PEG-LPs in primary liver endothelial cells (LECs) and in Hepa1-6 cell line. The RLTR peptide enhanced the cellular uptake of PEG-LPs and the maximum cellular uptake was observed within 3 mole% of RLTR peptide modification in both the cells (Fig. 1A-B) . 
In vivo selectivity of RLTR peptide
A biodistribution study of RLTR-PEG-LPs was carried out in order to confirm the targeting ability of RLTR-PEG modified LP. Compared to unmodified control LPs, RLTR-PEG-LPs were largely accumulated in the liver, with only negligible accumulation in the lung or spleen, within a very short time (Fig. 2) . The liver targeting ability of RLTR peptide was more than its ability to target lung or 245 spleen. We then obtained an in vivo image of the liver to check the distribution pattern of this RLTR-PEG modified LP in liver.
We then performed an in vivo accumulation study to verify our hypothesis outlined in the introduction part. We investigated the intrahepatic distribution of RLTR-PEG-LPs by confocal 250 microscopy. Rhodamine-labeled RLTR-PEG-LPs were widely distributed throughout the blood vessels (Fig. 3A) , and these intensities were essentially merged with the signal for Isolectin B4, a marker of endothelial cells (Fig. 3B and C ). These results demonstrate that RLTR-PEG-LPs efficiently target liver endothelial cells rather than hepatocytes. Furthermore, we compared the intrahepatic distribution pattern with RLTR-PEG-LPs and cationic LPs in order to evaluate the effect 255 of the cationic charge of the liposomal surface. The size and zeta-potential of the Rhodamine-labeled RLTR-PEG-LPs and cationic LPs was 125 nm, 26mV and 132 nm, 22 mV respectively. The intrahepatic distribution pattern of the cationic LPs was quite different from that of the RLTR-PEGLPs, in which the cationic LPs were gathered in particular spots (Fig. 3D ). In addition, these dots did not overlap with liver endothelial cells (Fig.3E-F) indicating that they were taken up by non-260 parenchymal cells such as kupffer cells or were merely aggregated LPs.
In vivo inhibition study
In order to examine some possible mechanisms of unique targeting ability of RLTR peptide into liver endothelial cells, comparative studies of RLTR and its reversed peptide sequence named as 265 KLGR were performed in the following part. Both RLTR-PEG-LPs and KLGR-PEG-LPs were accumulated along with the liver blood vessels (Fig. 4 A-B, G-H) . Next, accumulation of both labeled RLTR-PEG-LPs and KLGR-PEG-LP along with the liver blood vessels were dramatically inhibited by a pre-treatment with unlabeled RLTR-PEG-LPs or KLGR-PEG-LPs (Fig. 4C-D 
however, small portions of signal were remaining. In contrast, the accumulation of both labeled 270
RLTR-PEG-LPs or KLGR-PEG-LP was not reduced by the pre-treatment with unlabeled cationic
LPs (Fig. 4E-F, 4K-L) . The results generated in this study suggest that cationic charge is not the reason for this uptake and may be both RLTR peptide and its reverse sequence, the KLGR peptide has some specificity for liver endothelial cells. Possible interpretations will be discussed in the discussion section. 275
In vitro comparative inhibition study of RLTR-PEG-LPs
This experiment was performed to support the in vivo inhibition data. We compared the cellular uptake of both RLTR-PEG-LPs and KLGR-PEG-LPs with that of cationic-LPs under the inhibition with unlabeled RLTR-PEG-LPs or cationic-LPs. A comparative inhibition study with labeled andunlabeled LPs showed that the cellular uptake of labeled RLTR-PEG-LPs and KLGR-PEG-LPs were inhibited remarkably in the presence of a low amount of unlabeled RLTR-PEG-LPs and KLGR-PEG-LPs respectively (Fig. 5A-5B ). On the other hand, the cellular uptake of labeled cationic LPs was not inhibited to a significant extent by unlabeled cationic LPs (Fig. 5C) . The results generated in this study suggest that both the RLTR and KLGR peptide efficiently delivered the nanocarriers into 285 cells via a specific route, while cationic LPs were randomly taken up by cells. This conclusion is further supported by the in vivo comparative inhibition study.
Discussion
It has been reported that hepatocytes also express LDL receptors (Marit et al., 1998) and hepatocytes 290 comprise 80% of the total liver volume (Kmiec et al., 2001) . In a recent study it was also demonstrated that LDL is taken up by liver endothelial cells (Marit et al., 1998) . In this present study we attempted to design a new ligand for hepatocytes based on the ApoB-100 sequence of LDL. The newly designed peptide ligand is referred to as RLTR. The size of the RLTR-PEG-LPs increased with the increase of the amount of RLTR-PEG. The surface charge of the PEG-LPs remained 295 negative. However, the addition of the RLTR peptide resulted in a gradual increase in the surface charge of the PEG-LPs and a large difference in surface charge was observed between increments of RLTR-PEG of 1 mol% to 10 mol% (Table 1 ). This increment in surface charge of the RLTR-PEGLPs reflects the cationic properties of the RLTR peptide. RLTR-PEG-LPs showed a remarkable enhancement in cellular uptake compared to PEG-LPs in different cell types including liver 300 endothelial cell and Hepa 1-6 cell lines (Fig. 1) . In the biodistribution study it was also observed that most of the RLTR modified PEG-LP had accumulated in the liver rather than other organs such as lung or spleen (Fig. 2) . However, in confocal microscopy images it was observed that, RLTR-PEGLPs accumulated at high levels in liver blood vessels (Fig. 3A-C ) which indicate that these liposomes do not accumulate in hepatocytes. The cellular accumulation of RLTR-PEG-LPs was 305 significantly higher than that of cationic LPs (Fig. 3D-F) . Though the RLTR peptide is designed from LDL and there is previous report that LDL is rapidly taken up by LDL receptors, the peptide modified PEG-LP is highly accumulated in liver EC. It is possible that this carrier system has more specificity for liver EC, rather than hepatocytes. This surprising accumulation of this carrier system through blood vessels led us to conclude that this nanoparticle might be an ideal system for targeting 310 the liver endothelial cells. The finding that cationic peptides and lipids accumulate at high levels in endothelial cells of liver is attractive and interesting. There are very few reports of the use of cationic or neutral nano carriers to target liver endothelial cells (Bartsch et al., 2004 , Toriyabe et al., 2011 . It should be noted that, these systems failed to achieve high accumulation in liver endothelial cells.
Because of this, in this study we seized the opportunity to develop this nanocarier to target liver EC. 315
There are two possible reasons for the high accumulation of RLTR modified PEG-LP in liver EC.
Either the high cationic charge of the peptide is causing this high accumulation or the peptide sequence itself has specificity for liver endothelial cell. We then checked the specificity of both RLTR and its reverse sequence KLGR modified PEG-LP by both an in vitro and in vivo inhibition study. In the in vivo inhibition study we demonstrated that both the RLTR-PEG-LPs and KLGR-320 PEG-LPs uptake were inhibited by unlabeled RLTR-PEG-LPs and KLGR-PEG-LPs respectively (Fig. 4) . However, the cationic LPs did not affect its uptake both in vivo or in vitro (Fig.4 and 5 ).
Given these findings, the possibility of a higher accumulation in LEC is due to a higher cationic charge can be excluded. We then attempted to address the second possible reason of the higher accumulation in LEC, namely, the sequence of the peptide. We found that the sequence contain a 325 motif RKR which remains the same both in the RLTR and KLGR peptide, although the sequence is completely reversed. It has been reported that stearylated polyarginine and its derivatives, i.e. stearyl-(RXR) 4 mediates the efficient plasmid transfection in several cell lines ( Lehto et al., 2010) .
The RKR motif is similar as the RXR motif (Fig. 6 ). As our study shows that both the RLTR (RLTRKRGLK) and KLGR (KLGRKRTLR) modified PEG-LP are equally efficient in targeting 330 LEC, the possibility that the RKR sequence is responsible for this targeting cannot be completely excluded. There is another possibility, i.e. both peptides contain an RXXR motif. According to CendR theory this RXXR sequence is essential for a tissue penetrating property (Teesalu et al., 1997) . As our peptide sequence RLTR (RLTRKRGLK) and KLGR (KLGRKRTLR) both have the RXXR sequence and supporting CendR theory so there is another possibility that RLTR and KLGR 335 Table 1 Physicochemical properties of the RLTR-PEG-LP 360
% PEG Properties
PEG-LP RLTR-PEG-LP
Data are presented as the mean ± SD (n=3) 
